However, recent data shows that a significant portion of pharma product launches have underperformed in the past few years. To address this challenge, pharma companies are increasingly turning to sophisticated digital solutions to drive launch excellence and improve outcomes.

What it means to be digitally-forward at launch

Being "digitally-forward" at a pharma launch refers to the strategic integration of digital technologies and solutions in the planning and execution of product launches. This approach can help drive two separate but important goalslaunch sophistication for maximizing the impact of an individual launch and launch efficiency to drive scale across all launches.

Opportunities for digitally-forward solutions across a launch

Here are some ways in which pharma companies can use digitally-forward solutions across their entire product launch process to achieve more precise and accelerated outcomes:

• Shaping the market: In smaller markets, patients often spend years finding the right healthcare providers (HCPs). With the help of digital tools, pharma companies will be able to find and connect patients with the right type of specialist or even an individual physician, based on their symptoms and disease profile.

• Differentiating the product: Many pharma organizations use the same type of messaging in product launches due to the fear of overcomplicating the execution. By utilizing AI to analyze primary and secondary data, companies can create detailed customer profiles. This allows for personalized, customized messaging at the time of launch.

• Orchestrating customer experience: Opportunities to orchestrate customer experience is usually limited at a launch due to a lack of information about the customer. By using data from local healthcare markets, companies can orchestrate the ideal channel mix even at launch, with more personalization enhancements over time. This approach works even better if the company already has a presence with their target customer and can use information from previous launches to guide their efforts.

• Securing preferred access: Contracting is crucial for pharmaceutical market access, but many organizations negotiate poorly, leading to missed opportunities. Also, after securing a good contract, it can take a long time to communicate to the customers and the field about these wins, ultimately slowing down the process of getting products to market. By using contract simulation analytics and gross-to-net optimization, companies can drive plan negotiations and contracting and ensure fast and precise pull-through of access wins.

• Gaining data-driven insights: Most dashboards today only show a static view of current performance and treat issues separately, making it hard to see the full picture or to act quickly. An AI-powered launch insights hub simplifies this by collating all the data in one place and highlighting what actions should be taken. This helps launch teams spot problems early and adjust their strategy within days, instead of having to wait for months.

It is clear that to succeed in todays competitive pharma market, companies must embrace digital innovations at every stage of the launch. Pharma companies can also benefit from using generative AI in marketing their product launches by enhancing efficiency, personalization and content creation.

enhances pricing and reimbursement structures, which improve the accessibility of new drugs and treatments to patients.

What happens when pharmaceutical products gain market access?

When a product gains market access, it has all regulatory approvals and is priced fairly for its launch on the market. However, achieving this access is a long-drawn process. Pharmaceutical companies should be able to communicate the product value to stakeholders. Digital strategy consulting firms' expert guidance and strategic solutions for pharma companies make this long journey easy.

How does healthcare strategy support pharma market access?

Market access is essential during the product lifecycle. Healthcare consulting firms help pharma clients navigate the complex roadmap of the commercial launch of new drugs and treatments. Here are some areas of their strategic consultation: -

Regulatory compliance: These consulting firms use real-world evidence and clinical data to ensure regulatory compliance for new drug launches.

Pricing strategy: Advanced technologies and vast data sets offer pricing strategies for product value propositions.

Market entry: They give pharma companies relevant knowledge about the right market entry point and the right channels.

Process optimization: Their strategic consultation helps pharmaceutical companies optimize processes for faster drug launches.

The role of market access in the pharmaceutical industry

Regulatory approval

Regulatory approval for a drug launch is mandatory in the market. Market access data allows pharma companies to prepare for regulatory approval. The regulatory bodies evaluate a new drug or treatment on its safety, efficacy, need, and quality.

Reimbursement strategy

Payer negotiation is a major part of devising a reimbursement strategy for pharmaceutical companies. Market access helps plan strategies to secure favorable reimbursement terms. This way, patients have access to necessary medicine at a fair price, and pharma companies get profitable pricing.

Stakeholder engagement

Government bodies, healthcare professionals, payers, and patients are key stakeholders in the pharmaceutical industry. Market access strategies enable companies to engage these stakeholders for a successful drug launch.

Market access strategies are at the core of pharmaceutical drug and treatment launches on the market. They utilize real-world data and clinical data to form a robust plan for the success of a new product launch.